ERBB2 and breast cancer: Targeted therapies, such as the mTOR inhibitor everolimus22, the latest CDK4/6 inhibitor, palbociclib23, for hormone receptor-positive breast cancer, and trastuzumab24 for HER2-positive breast cancer, have made certain advancements in the treatment of breast cancer.